BAP1 and neoplasm: Metastatic sites demonstrated different characteristics based on whether they harbored mutations in either BAP1 or PBRM1. BAP1-driven tumors were characterized by increased tumor heterogeneity as well as high genomic instability and may thus be vulnerable to immunotherapeutic targets.